UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as COO

UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Stephen Mullennix as Chief Operating Officer with overall responsibility for the Company’s operations.  Mr. Mullennix will join the senior management team and will report to Ron Bentsur, UroGen’s Chief Executive Officer.

As quoted in the press release:

“I am delighted to have Stephen join our team as we continue to advance our product candidates through the regulatory approval process,” said Mr. Bentsur. “Stephen’s deep experience in building commercial enterprises with breakthrough technology, unique operational perspective and overall knowledge as an investment and finance professional will drive value as UroGen continues to execute on its strategic vision.”

Click here to read the full press release.